Share Price | Gyre Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Gyre Therapeutics, Inc. do?

Overview: Gyre Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Market cap: Micro CapKey Metrics: Industry: Pharmaceuticals & Biotechnology Dividend Yield: 0.00% Debt Equity: -999,999.00 Return on Equity: -999,999.00% Price to Book: 0.00 Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Gyre Therapeutics, Inc. overvalued or undervalued?

As of 9 May 2025, the valuation grade for Gyre Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. The P/E ratio stands at 105.51, significantly higher than the industry average, while the EV to EBITDA ratio is 57.93, further suggesting a premium valuation. The lack of a PEG ratio indicates that growth expectations may not justify the current price levels.In comparison to peers, Gyre Therapeutics is notably more expensive, with its P/E ratio far exceeding typical valuations in the pharmaceuticals and biotechnology sector. For instance, while Gyre's P/E is 105.51, other companies in the industry may have much lower ratios, reflecting a more reasonable valuation. Additionally, the company's stock has underperformed against the S&P 500, with a year-to-date return of -36.45% compared to the S&P 500's 12.22%, reinforcing the notion that the stock may be overvalued given its performance trajectory.

Q: Is Gyre Therapeutics, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Gyre Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD, KST, and Dow Theory show mildly bullish signals. However, Bollinger Bands remain bearish across both weekly and monthly time frames. The stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -36.45% versus the S&P 500's 12.22%, and a one-year return of -44.56% compared to 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

183.67 k

Shareholding (Sep 2025)

FII

0.30%

Held by 17 FIIs

DII

97.33%

Held by 3 DIIs

Promoter

0.00%

What does Gyre Therapeutics, Inc. do?

22-Jun-2025

Gyre Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently showing no dividend yield and negative financial metrics. No additional company details are available.

View full answer

Is Gyre Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of May 9, 2025, Gyre Therapeutics, Inc. is considered overvalued with a P/E ratio of 105.51 and an EV to EBITDA ratio of 57.93, significantly higher than industry averages, and has underperformed the S&P 500 with a year-to-date return of -36.45%.

View full answer

Is Gyre Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Gyre Therapeutics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators suggest mild bullishness, despite significant underperformance against the S&P 500, with year-to-date and one-year returns of -36.45% and -44.56%, respectively.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Positive results in Sep 25

RAW MATERIAL COST(Y) Fallen by 1.65% (YoY)
NET SALES(Q) Highest at USD 30.56 MM
OPERATING PROFIT(Q) Highest at USD 7.58 MM

With ROE of 7.38%, it has a expensive valuation with a 8.23 Price to Book Value

Majority shareholders : Mutual Funds

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 753 Million (Micro Cap)

P/E

112.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.58

Return on Equity

-999,999.00%

Price to Book

7.38

Revenue and Profits:

Net Sales:

31 Million

(Quarterly Results - Sep 2025)

Net Profit:

6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.59%

6 Months

8.01%

1 Year

-22.41%

2 Years

-61.44%

3 Years

143.33%

4 Years

-2.46%

5 Years

-90.32%

Gyre Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

41.49%

EBIT Growth (5y)

17.39%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.95%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

112

Industry P/E

Price to Book Value

8.23

EV to EBIT

75.34

EV to EBITDA

61.51

EV to Capital Employed

18.38

EV to Sales

6.89

PEG Ratio

Dividend Yield

ROCE (Latest)

24.40%

ROE (Latest)

7.38%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 10 Schemes (2.37%)

Foreign Institutions

Held by 17 Foreign Institutions (0.3%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 20.00% vs -20.31% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 103.45% vs -61.33% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "30.60",
          "val2": "25.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.60",
          "val2": "4.70",
          "chgp": "61.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.90",
          "val2": "2.90",
          "chgp": "103.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "226.60%",
          "val2": "166.10%",
          "chgp": "6.05%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.78% vs 10.95% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 120.94% vs -2,088.37% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.80",
          "val2": "113.50",
          "chgp": "-6.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "17.80",
          "val2": "20.30",
          "chgp": "-12.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "7.20",
          "val2": "-95.10",
          "chgp": "107.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.90",
          "val2": "-85.50",
          "chgp": "120.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.50%",
          "val2": "169.40%",
          "chgp": "-1.59%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

30.60

25.50

20.00%

Operating Profit (PBDIT) excl Other Income

7.60

4.70

61.70%

Interest

0.00

Exceptional Items

-0.00

-0.20

100.00%

Consolidate Net Profit

5.90

2.90

103.45%

Operating Profit Margin (Excl OI)

226.60%

166.10%

6.05%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 20.00% vs -20.31% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 103.45% vs -61.33% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

105.80

113.50

-6.78%

Operating Profit (PBDIT) excl Other Income

17.80

20.30

-12.32%

Interest

0.00

Exceptional Items

7.20

-95.10

107.57%

Consolidate Net Profit

17.90

-85.50

120.94%

Operating Profit Margin (Excl OI)

153.50%

169.40%

-1.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -6.78% vs 10.95% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 120.94% vs -2,088.37% in Dec 2023

All Annual Results

Company CV

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available